J. Christopher States, Ph.D.


B.S., Biochemistry, State University of New York at Buffalo, Buffalo, NY; 1974
Ph.D., Molecular Biology and Pathology, Albany Medical College, Union University, Albany, NY; 1980
Postdoctoral Fellowship, Department of Medical Biochemistry, University of Calgary, Calgary, Alberta, Canada; 1980-1984 

Curriculum Vitae

Current Positions:

Professor and Vice-Chair for Research, Department of Pharmacology and Toxicology, University of Louisville
Associate Dean for Research, Medical School, University of Louisville
Distinguished University Scholar, University of Louisville
Director, Center for Integrative Environmental Health Sciences
Member, Experimental Therapeutics & Diagnostics Program, Brown Cancer Center

Contact Information:

Department of Pharmacology & Toxicology
Clinical & Translational Research Building, Room 304
505 South Hancock Street
University of Louisville
Louisville, KY 40202
Phone:  502/852-5347
Email:  jcstates@louisville.edu

Research Description: 

The major interests of the laboratory are arsenic toxicology, DNA repair and development of mitosis disrupting drugs for cancer chemotherapy.  Currently, the laboratory is investigating the role of miRNA dysregulation in arsenic-induced skin carcinogenesis.  The lab is determining miRNA profiles of arsenic-induced squamous and basal cell carcinomas and premalignant hyperkeratoses.  In parallel, the lab is characterizing miRNA expression changes that occur during arsenic transformation of a human keratinocyte cell line.  The interest in mitotic disruption includes investigation of miR-186 overexpression effects on chromatid separation and compounds that inhibit function of the anaphase promoting complex/cyclosome.  Other interests include induction of chronic adult diseases by early life/in utero arsenic exposure and enhancement of cisplatin sensitivity by co-administration of arsenicals. 

Literature Cited: 

  1.   Banerjee M, Ferragut Cardoso A, Al-Eryani L, Pan J, Kalbfleisch TS, Srivastava S, Rai SN, States JC.  Dynamic alteration in miRNA and mRNA expression profiles at different stages of chronic arsenic exposure-induced carcinogenesis in a human cell culture model of skin cancer.  Archives of Toxicology 2021 Jul;95(7):2351-2365.  doi: 10.1007/s00204-021-03084-2.  Epub 2021 May 25.  PMID: 34032870.  PMCID: PMC8241660.
  2. Ferragut Cardoso AP, Banerjee M, Nail AN, Lykoudi A, States JC.  miRNA dysregulation is an emerging modulator of genomic instability.  Seminars in Cancer Biology 2021 Nov;76:120-131.  doi: 10.1016/j.semcancer.2021.05.004.  Epub 2021 May 9.  PMID: 33979676.  Review.
  3. Leggett CS, Doll MA, States JC, Hein DW.  Acetylation of putative arylamine and alkylaniline carcinogens in immortalized human fibroblasts transfected with rapid and slow acetylator N-acetyltransferase 2 haplotypes.  Archives of Toxicology 2021 Jan;95(1):311-319.  doi: 10.1007/s00204-020-02901-4.  Epub 2020 Nov 2.  PMID: 33136180.  PMCID: PMC7855884.
  4. Ferragut Cardoso AP, Udoh KT, States JC.  Arsenic-induced changes in miRNA expression in cancer and other diseases.  Toxicology & Applied Pharmacology 2020 Dec 15;409:115306.  doi: 10.1016/j.taap.2020.115306.  Epub 2020 Oct 28.  PMID: 33127375.  PMCID: PMC7772821.
  5. Banerjee M, Ferragut Cardoso AP, Lykoudi A, Wilkey DW, Pan J, Watson WH, Garbett NC, Rai SN, Merchant ML, States JC.  Arsenite exposure displaces zinc from ZRANB2 leading to altered splicing.  Chemical Research in Toxicology 2020 Jun 15;33(6):1403-1417. doi: 10.1021/acs.chemrestox.9b00515.  Epub 2020 Apr 27. PMID: 32274925.  PMCID: PMC7405655.
  6. Chandrasekaran B, Dahiya NR, Tyagi A, Kolluru V, Saran U, Baby BV, States JC, Haddad AQ, Ankem MK, Damodaran C.  Chronic exposure to cadmium induces a malignant transformation of benign prostate epithelial cells.  Oncogenesis 2020 Feb 17;9(2):23.  doi: 10.1038/s41389-020-0202-7.  PMID: 32066655.  PMCID PMC7026396.
  7. Young JL, Yan X, Xu J, Yin X, Zhang X, Arteel GE, Barnes GN, States JC, Watson WH, Kong M, Cai L, Freedman JH.  Publisher Correction: Cadmium and high-fat diet disrupt renal, cardiac and hepatic essential metals.  Scientific Reports 2020 Feb 10;10(1):2609.  doi: 10.1038/s41598-020-58517-2.  Erratum for: Scientific Reports 2019 Oct 11;9(1):14675.  PMID: 32042093.  PMCID: PMC7010654.
  8. Wu J, Ferragut Cardoso AP, States VAR, Al-Eryani L, Doll M, Wise SS, Rai SN, States JC.  Overexpression of hsa-miR-186 induces chromosomal instability in arsenic-exposed human keratinocytes.  Toxicology & Applied Pharmacology 2019 Sep 1;378:114614.  doi: 10.1016/j.taap.2019.114614.  Epub 2019 Jun 6.  PMID: 31176655.  PMCID: PMC6746570.
  9. Al-Eryani L, Jenkins SF, States VA, Pan J, Malone JC, Rai SN, Galandiuk S, Giri AK, States JC.  miRNA expression profiles of premalignant and malignant arsenic-induced skin lesions.  PLoS One 2018 Aug 16;13(8):e0202579.  doi: 10.1371/journal.pone.0202579.  PMID: 30114287.  PMCID: PMC6095593.
  10. Young JL, Cai L, States JC.  Impact of prenatal arsenic exposure on chronic adult diseases.  Systems Biology in Reproductive Medicine 2018 Dec;64(6):469-483.  doi: 10.1080/19396368.2018.1480076.  Epub 2018 Jun 6.  PMID: 29873257.  PMCID: PMC6291241.
  11. Cardoso APF, Al-Eryani L, States JC.  Arsenic-induced carcinogenesis: The impact of miRNA dysregulation.  Toxicological Sciences 2018 Oct 1;165(2):284-290.  doi: 10.1093/toxsci/kfy128.  PMID: 29846715; PMCID: PMC6154275.
  12. Al-Eryani L, Waigel S, Tyagi A, Peremarti J, Jenkins SF, Damodaran C, States JC.  Differentially expressed mRNA targets of differentially expressed miRNAs predict changes in the TP53 axis and carcinogenesis-related pathways in human keratinocytes chronically exposed to arsenic.  Toxicological Sciences 2018 Apr 1;162(2):645-654. doi: 10.1093/toxsci/kfx292. PMID: 29319823; PMCID: PMC5889014.
  13. Stepp MW, Doll MA, Carlisle SM, States JC, Hein DW.  Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.  MolecularCarcinogenesis 2018 Apr;57(4):549-558.  doi: 10.1002/mc.22779.  Epub 2018 Feb 3.  PMID: 29315819. PMCID: PMC5832614.
  14. Al-Eryani L, Waigel S, Jala V, Jenkins SF, States JC.  Cell cycle pathway dysregulation in human keratinocytes during chronic exposure to low arsenite.  Toxicology & Applied Pharmacology 2017 Sep 15;331:130-134.  doi: 10.1016/j.taap.2017.06.002.  Epub 2017 Jun 14.  PMID: 28595984.  PMCID: PMC5957280.
  15. Muenyi CS, Ljungman M, States JC.  Arsenic disruption of DNA damage responses-potential role in carcinogenesis and chemotherapy.  Biomolecules 2015 Sep 24;5(4):2184-93.  doi: 10.3390/biom5042184.  PMID: 26404387.  PMCID: PMC4693233.
  16. States JC.  Disruption of mitotic progression by arsenic.  Biology of Trace Elements Research 2015 Jul;166(1):34-40.  doi: 10.1007/s12011-015-0306-7.  Epub 2015 Mar 22.  PMID: 25796515.  PMCID: PMC7098731.
  17. States JC, Ouyang M, Helm CW.  Systems approach to identify environmental exposures contributing to organ-specific carcinogenesis.  CancerEpidemiology 2014 Jun;38(3):321-7.  doi: 10.1016/j.canep.2014.03.005.  Epub 2014 Apr 12.  PMID: 24721284.  PMCID: PMC4035223.

PubMed Information